Meanwhile, the BSE Sensex was down 2.26 points or 0.01% to 16,879.90.
On BSE, 7,327 shares were traded in the counter as against average daily volume of 30,780 shares in the past two weeks.
The stock hit a high of Rs 356.90 and a low of Rs 348.25 so far during the day.
The Natco Pharma stock had tumbled 5.96% to settle at Rs 350.60 on Monday, 25 June 2012, after the company during trading hours on Monday, 25 June 2012 said the US District Court for the Southern District of New York, in a ruling delivered on 22 June 2012 has upheld the contention of Teva Pharmaceuticals that Natco Pharma's abbreviated new drug application (ANDA) for the generic version of Copaxone infringes all the asserted claims of Teva Pharmaceuticals.
Natco Pharma had filed, with its partner Mylan Inc, in June 2008, an ANDA seeking approval for marketing of the generic version of the relapsing, remitting multiple sclerosis drug Copaxone and obtained a Para IV certification which essentially challenges the existing patents held by Teva Pharmaceuticals.
Natco Pharma said it is disappointed with the Court's ruling on Copaxone. While the company has not yet had the opportunity to review the Court's opinion, it will fully investigate all available options for appeal once the Court's full opinion becomes available, Natco Pharma said in a statement.
Natco Pharma's consolidated net profit fell 12% to Rs 12.65 crore on 33.3% growth in net sales to Rs 141.66 crore in Q4 March 2012 over Q4 March 2011.
Natco Pharma manufactures generic dosage forms, bulk actives and intermediates for the Indian and international markets.